Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia

Published:2007 Issue:1 Volume:112 Page:119-128
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Del Poeta Giovanni,Del Principe Maria Ilaria,Buccisano Francesco,Maurillo Luca,Capelli Giovanni,Luciano Fabrizio,Perrotti Alessio Pio,Degan Massimo,Venditti Adriano,de Fabritiis Paolo,Gattei Valter,Amadori Sergio

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference41 articles.

1. Clinical staging of chronic lymphocytic leukemia

2. A clinical staging system for chronic lymphocytic leukemia.Prognostic significance

3. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia

4. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.

5. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maintenance therapy for chronic lymphocytic leukaemia;Cochrane Database of Systematic Reviews;2024-01-04

2. Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab;Annals of Allergy, Asthma & Immunology;2023-06

3. Effect of rituximab dose on induction therapy in ABO-incompatible living kidney transplantation;Medicine;2021-03-12

4. Maintenance therapy for chronic lymphocytic leukaemia;Cochrane Database of Systematic Reviews;2019-11-12

5. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance;Haematologica;2019-03-19